EVP, General Counsel and Strategic Initiatives
Mr. Kennedy joined Amarin in December 2011 as senior vice president, general counsel. He has over 20 years of experience working with life science companies at every stage of development. Prior to Amarin, Mr. Kennedy served as vice president, general counsel of Transcept Pharmaceuticals, Inc., through its public company transition, strategic collaboration negotiation and lead product marketing approval. Mr. Kennedy also served as chief corporate counsel, then acting chief legal officer with Eyetech Pharmaceuticals, Inc. through its public company transition and product commercialization, and vice president and U.S. counsel, corporate business development, with Elan Corporation, plc. Mr. Kennedy previously practiced law with Orrick, Herrington & Sutcliffe LLP. Mr. Kennedy was honored by the President of Ireland as one of the inaugural “Irish Life Science 50" which recognized Irish-Americans for contributions to the life science industry and by Financial Times in its recognition of Amarin in 2016 as a standout legal innovator in its North American Most Innovative Lawyers awards.
commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids